PIO and Placebo formulations are considered compatible. As they have the same qualitative composition as SPIOMET clinical trials

A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS).

This study is looking at a new combination of medicines (SPIOMET) to see if it helps teenage girls and young women with Polycystic Ovary Syndrome (PCOS) ovulate more regularly. It will also check how safe and well-tolerated the treatment is.